| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14656566.2016.1254189 |
| P698 | PubMed publication ID | 27785919 |
| P50 | author | Santiago Perez-Lloret | Q67389929 |
| P2093 | author name string | Francisco J Barrantes | |
| María Cecilia Peralta | |||
| P2860 | cites work | The history of dopamine and levodopa in the treatment of Parkinson's disease | Q22252881 |
| Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models | Q24683059 | ||
| Pedunculopontine Nucleus Stimulation: Where are We Now and What Needs to be Done to Move the Field Forward? | Q26852043 | ||
| Local control of striatal dopamine release | Q26861838 | ||
| Striatal cholinergic interneuron regulation and circuit effects | Q26863113 | ||
| Signal integration in the endoplasmic reticulum unfolded protein response | Q27860577 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. | Q33195032 | ||
| Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease | Q33567182 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease | Q33607256 | ||
| The neurobiological basis of cognitive impairment in Parkinson's disease | Q33724698 | ||
| Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease | Q33917311 | ||
| Rivastigmine for dementia associated with Parkinson's disease | Q33983707 | ||
| Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease | Q34135495 | ||
| Cholinergic interneuron characteristics and nicotinic properties in the striatum | Q34159449 | ||
| Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study | Q34170501 | ||
| Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior | Q34304101 | ||
| Neural substrates of cognitive subtypes in Parkinson's disease: a 3-year longitudinal study. | Q34374245 | ||
| Emerging structure of the nicotinic acetylcholine receptors | Q34522883 | ||
| Pathophysiology and treatment of psychosis in Parkinson's disease: a review | Q34610608 | ||
| Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep | Q34985659 | ||
| Unfolding the role of protein misfolding in neurodegenerative diseases | Q35038274 | ||
| Clinical markers for identifying cholinergic deficits in Parkinson's disease | Q35054623 | ||
| Pedunculopontine nucleus area oscillations during stance, stepping and freezing in Parkinson's disease | Q35080746 | ||
| Novel insights into muscarinic acetylcholine receptor function using gene targeting technology | Q35198037 | ||
| Modeling Parkinson's disease falls associated with brainstem cholinergic systems decline | Q35360176 | ||
| Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. | Q35486482 | ||
| Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study | Q35488511 | ||
| Cholinergic neurons in the dorsomedial hypothalamus regulate mouse brown adipose tissue metabolism. | Q35644503 | ||
| Novel fast adapting interneurons mediate cholinergic-induced fast GABAA inhibitory postsynaptic currents in striatal spiny neurons | Q35876088 | ||
| Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease | Q35944999 | ||
| Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions | Q36042479 | ||
| Non-motor dysfunction in Parkinson's disease | Q36756269 | ||
| Attentional Control of Gait and Falls: Is Cholinergic Dysfunction a Common Substrate in the Elderly and Parkinson's Disease? | Q36881389 | ||
| Regional impairment of cerebral oxidative metabolism in Parkinson's disease | Q36991466 | ||
| Gait disorders and balance disturbances in Parkinson's disease: clinical update and pathophysiology | Q37209410 | ||
| Gait speed in Parkinson disease correlates with cholinergic degeneration | Q37251657 | ||
| Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment | Q37449905 | ||
| History of falls in Parkinson disease is associated with reduced cholinergic activity | Q37459699 | ||
| The cholinergic system and Parkinson disease | Q37671065 | ||
| Cholinergic dysfunction in Parkinson's disease | Q37709932 | ||
| Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease | Q37727311 | ||
| The interplay of cholinergic function, attention, and falls in Parkinson's disease | Q37928585 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease | Q37948713 | ||
| Normal and pathological gait: what we learn from Parkinson's disease | Q38023268 | ||
| An ERcentric view of Parkinson's disease | Q38076982 | ||
| The practical management of cognitive impairment and psychosis in the older Parkinson's disease patient | Q38083586 | ||
| Structural insights into Cys-loop receptor function and ligand recognition | Q38121351 | ||
| Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases | Q38195215 | ||
| Cognitive impairment and dementia in Parkinson's disease: practical issues and management. | Q38206499 | ||
| The prevalence of Parkinson's disease: a systematic review and meta-analysis | Q38224356 | ||
| Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. | Q38249953 | ||
| Parkinson's disease and sleep/wake disturbances | Q38357853 | ||
| Phylogenetic conservation of protein-lipid motifs in pentameric ligand-gated ion channels. | Q38403758 | ||
| Review of delirium in patients with Parkinson's disease. | Q38469040 | ||
| Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection | Q38558848 | ||
| New clinical trials for nonmotor manifestations of Parkinson's disease | Q38587090 | ||
| Acetylcholinesterase Inhibitors for Delirium in Older Adults | Q38662396 | ||
| Atropinic (Anticholinergic) Burden in Parkinson's Disease | Q38793600 | ||
| Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia | Q40098504 | ||
| Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients | Q40627346 | ||
| Low-frequency stimulation of the pedunculopontine nucleus affects gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats | Q40857703 | ||
| Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia | Q41905810 | ||
| Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). | Q42453793 | ||
| Deficits in motor performance after pedunculopontine lesions in rats--impairment depends on demands of task | Q42461730 | ||
| Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. | Q42462932 | ||
| Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson's disease dementia: a retrospective analysis of a double-blind trial and an open-label extension | Q42640493 | ||
| Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. | Q42652289 | ||
| Sleep induced by stimulation in the human pedunculopontine nucleus area | Q43902181 | ||
| Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease | Q43974492 | ||
| The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years | Q44801054 | ||
| Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems. | Q46048283 | ||
| Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease | Q46169188 | ||
| Low-frequency versus high-frequency stimulation of the pedunculopontine nucleus area in Parkinson's disease: a randomised controlled trial | Q48032945 | ||
| Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease | Q48076091 | ||
| Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study | Q48084523 | ||
| Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism. | Q48221473 | ||
| Functional evaluation of central cholinergic circuits in patients with Parkinson's disease and REM sleep behavior disorder: a TMS study | Q48227407 | ||
| Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. | Q48312054 | ||
| Unilateral pedunculopontine stimulation improves falls in Parkinson's disease | Q48428197 | ||
| Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons | Q48441601 | ||
| Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. | Q48452740 | ||
| Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease | Q48870423 | ||
| Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial | Q48957826 | ||
| Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. | Q50745621 | ||
| Dementia and survival in Parkinson disease: a 12-year population study. | Q51892520 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| pharmacotherapy | Q701216 | ||
| P304 | page(s) | 2405-2415 | |
| P577 | publication date | 2016-10-27 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration | |
| P478 | volume | 17 |
| Q38643289 | Cortical afferent inhibition abnormalities reveal cholinergic dysfunction in Parkinson's disease: a reappraisal |
| Q47117943 | Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines? |
| Q53697967 | Managing Gait, Balance, and Posture in Parkinson's Disease. |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q96348327 | The role of nicotinic cholinergic neurotransmission in delusional thinking |
| Q64862645 | Treatment of Parkinson's disease psychosis. |
Search more.